



The
COMMONWEALTH
FUND

Affordable, quality health care. For everyone.



Can We Lower Low-Value Care? Policy Measures and Lessons in Australia, Canada, England, France, and Germany

Reinhard Busse, Prof. Dr. med. MPH FFPH

Dept. Health Care Management, Technische Universität Berlin, Germany

with



Verena Vogt, Adam Elshaug, Tai M Huynh, Wendy Levinson,
Hugh Alderwick, Kalipso Chalkidou & Isabelle Durand-Zaleski

What is the problem?

Health care of unknown benefit,
of no benefit,
superseded by better alternatives or
with more harm than benefit
provides low (or no) medical value
but consumes health care resources (both
human and financial resources) which could be
saved or used otherwise producing more value


How big is the problem? For the U.S., large - but cited figures are an underestimation of the size

(26 selected services only; Berwick calculates \$ 192 bn/ 7% spending on overtreatment)



Source: Schwartz et al., JAMA Internal Medicine, 2014

Have we only just discovered the issue?



No – we have known about it as a component of other terms for a long time:

- Cochrane's *Effectiveness and Efficiency* (1972) → evidence-based medicine,

clinical guidelines, Cochrane Collaboration




- Wennberg's *Small Area Variations in Health Care Delivery* (1973)

Table 3. Variation in number of surgical procedures performed per 10,000 persons for the 13 Vermont hospital service areas and comparison populations, Vermont, 1969. (Rates adjusted to Vermont age composition.)

Surgical procedure	Lowest two areas	Entire state	Highest two areas
Tonsillectomy	13 32	43	85 151
Appendectomy	10 15	18	27 32
Hemorrhoidectomy	2 4	6	9 10

- U.S. Office for Technology Assessment → Health Technology Assessment (1975)



Have we only just discovered the issue?

- Brook's assessment of the appropriateness of medical technologies (1986)
 - IOM's *To Err is Human: Building a Safer Health System* (2000) → Patient safety
 - "Waste" (Fuchs 2009, Berwick 2012)
 - "Disinvestment" ...
- confusion (not only) among policy-makers about "low-value" vs. "ineffective", "inappropriate", "unnecessary" or "inefficient" care, "misuse", "overuse, -diagnosis, -treatment", "waste" etc.

Aims of the paper/ presentation/ panel

- To develop a policy-oriented framework of low-value care and strategies to reduce it
- to present—and categorize—strategies applied by policymakers and purchasers, both implemented and/or discussed, in five countries (Australia, Canada, England, France, and Germany), and
- to discuss these strategies in relation to their results and transferability.

The framework to classify “low-value care”

	<i>“All patients” potentially receiving the technology</i>	<i>All patients belonging to one or more well- defined subgroups (by age, indication ...)</i>	<i>“Certain patients” (individual medical criteria or preferences are relevant)</i>
	PSA screening	PSA screening >75 yrs.	C-section
	Testing for CRP	Carotid endarterectomy in asymptomatic patients	Many cardiac procedures
	Chlamydia screening	Imaging for non-specific low back pain	Knee arthroscopy
		Stress-testing for stable coronary disease	
		Antibiotics for viral infections	
		Vertebroplasty for osteoporotic fracture	

The framework to classify “low-value care”

	<i>“All patients” potentially receiving the technology</i>	<i>All patients belonging to one or more well- defined subgroups (by age, indication ...)</i>	<i>“Certain patients” (individual medical criteria or preferences are relevant)</i>
Harm > benefit		Antibiotics for viral infections	
Benefit not proven			
No benefit or not better than <u>alterna- tive</u> (e.g., outdated)	Low-value pharmaceuticals	FOCUS OF “LOW-VALUE CARE”	
Benefit better but cost-outcome relation worse		MRI for breast cancer (except after mastectomy)	C-section only as patient/ physician preference
Equal benefit but provision inefficient (e.g., inpatient instead of day-care)	Cataract surgery as inpatient	Inpatient cataract surgery (except if severe co-morbidity)	

The framework to classify “low-value care”

	<i>“All patients” potentially receiving the technology</i>	<i>All patients belonging to one or more well- defined subgroups (by age, indication ...)</i>	<i>“Certain patients” (individual medical criteria or preferences are relevant)</i>
Harm > benefit	SAFETY		
Benefit not proven	EFFECTIVE- NESS	FOCUS OF “LOW-VALUE CARE”	APPROPRIATENESS (“INDICATION QUALITY”)
No benefit or not better than <u>alterna- tive</u> (e.g., outdated)			
Benefit better but cost-outcome relation worse		“COST- EFFECTIVENESS”/ “COST-BENEFIT”	
Equal benefit but provision inefficient (e.g., inpatient instead of day-care)	EFFICIENCY		

Overtreatment vs. other forms of waste

	<i>Failures of care coordination</i> 5%			
	UNSAFE (MISUSE/ BAD QUALITY)			
<i>Failures of care coordination</i> 1%	INEFFECTIVE	“LOW-VALUE CARE” → OVERTREATMENT/ BAD INDICATION QUALITY	INAPPROPRIATE → OVERTREATMENT/ BAD INDICATION QUALITY	<i>Fraud and abuse</i> 7%
		NOT COST-EFFECTIVE		
	INEFFICIENT (MISUSE/ ECONOMIC OVERUSE)			
	<i>Administrative complexity</i>			
	9%		<i>Pricing failures</i>	5%

Strategies against “low-value care” – the horizontal view

	<i>“All patients” potentially receiving the technology</i>	<i>All patients belonging to one or more well- defined subgroups (by age, indication ...)</i>	<i>“Certain patients” (individual medical criteria or preferences are relevant)</i>
Harm > benefit	Revoke license		
Benefit not proven	Make HTA mandatory for coverage		
No benefit or not better than <u>alternative</u> (e.g., outdated)	Remove from benefit package/ reimburse equally to alternative		
Benefit better but cost-outcome relation worse	Couple reimbursement to value (rather than effort/ costs of provision)		
Equal benefit but provision inefficient (e.g., inpatient instead of day-care)	Provide equal reimbursement		

Strategies against “low-value care” – the vertical view

	“All patients” potentially receiving the technology	All patients belonging to one or more well- defined subgroups (by age, indication ...)	“Certain patients” (individual medical criteria or preferences are relevant)
Harm > benefit	<ul style="list-style-type: none"> • <i>Remove from benefit package</i> 	<ul style="list-style-type: none"> • <i>Restrict coverage to certain indications/ subgroups</i> • <i>Information campaigns / guidelines to providers</i> • <i>Selective non-payment</i> • <i>Bundled payment</i> • <i>Information campaigns to population/ patients</i> 	<ul style="list-style-type: none"> • <i>Quality measurement (outcome)</i> • <i>Utilization review</i> • <i>Bundled payment</i> • <i>Information campaigns/ guidelines</i>
Benefit not proven			
No benefit or not better than <u>alternative</u> (e.g., outdated)			
Benefit better but cost-outcome relation worse			
Equal benefit but provision inefficient (e.g., inpatient instead of day-care)			

Strategies against “low-value care” – the mixed view

	<i>“All patients” potentially receiving the technology</i>	<i>All patients belonging to one or more well- defined subgroups (by age, indication ...)</i>	<i>“Certain patients” (individual medical criteria or preferences are relevant)</i>
Harm > benefit	<div style="background-color: red; color: white; padding: 5px; text-align: center;"> Primarily ex-ante and regulatory (license/ HTA/ coverage) </div>		
Benefit not proven			
No benefit or not better than <u>alternative</u> (e.g., outdated)			
Benefit better but cost-outcome relation worse			
Equal benefit but provision inefficient (e.g., inpatient instead of day-care)			
		<p style="text-align: center;"> <u>Ex-ante</u> = steering behaviour, possibly prior authorization & <u>ex-post</u> = utilization review </p>	<p style="text-align: center;"> <u>Ex-post</u> = quality indicators and utilization review & <u>ex-ante</u> = steering behaviour </p>

Conclusions

- Problem is large and necessitates a broad strategic approach (no country has done that yet)
- Mixture of regulation (license/ coverage), financing and information required, both ex-ante and ex-post
- But measuring the value of care is difficult and achieving consensus on measures often impossible
- Where measures against low-value are implemented, decisions are sometimes successfully challenged → strong political commitment required
- Value is often dependent on the clinical context, not very suited to strong ex-ante strategies → area of information mixed with utilization review